Skip to content

KEYPHARM

Active
Public limited companyfounded 2006active for 20 yearsSiemenslaan 11, 8020 Oostkamp, BelgiumKBO/BCE: BE 0883.397.311

Acts, filings and financial milestones

Deadline for the 2026 accounts: 31-07-2027
2026
10-07
NBB filing Annual accounts 2025 filedNBB
full format · 21 days before the deadline
2025
31-12
Financial Highest result from 2018 to 2025net €1.6m ▲58%
The operating result of €2.0m and the net result of €1.6m are both a record.
31-12
Financial Equity above €5mequity €5.2m ▲14.7%
With a profit in every financial year since 2018, equity grows to €5.2m.
09-09
NBB filing Annual accounts 2024 filedPDF
full format · 40 days late
2024
23-09
Gazette deed Appointment: AUDITAS BEDRIJFSREVISOREN BV (statutory auditor)
Permanent representatives: Sven Vansteelant and Jens Vanden Driessche4 points ▸
  • General meeting, 28-06-2024
  • Auditor appointment, AUDITAS BEDRIJFSREVISOREN BV (statutory auditor)
  • Permanent representative, Sven Vansteelant
  • Permanent representative, Jens Vanden Driessche

Open the act in the Belgian Official Gazette

23-07
NBB filing Annual accounts 2023 filedPDF
full format · 8 days before the deadline
2023
26-07
NBB filing Annual accounts 2022 filedPDF
full format · 5 days before the deadline
23-01
Gazette deed Amendment of the articles · Miscellaneous
Purpose change · Power of attorney6 points ▸
  • Other provision, “oprichting onder benaming PROSANDIS”, 04-09-2006 (deed in Dutch)
  • General meeting, 16-12-2022
  • Other provision, “kennisname verslag bestuursorgaan over uitbreiding voorwerp, verslag van het bestuursorgaan met verantwoording nopens de uitbreiding van het voorwerp” (deed in Dutch)
  • Purpose change
  • Power of attorney
  • Power of attorney, François-Xavier Willems

Open the act in the Belgian Official Gazette

05-01
Gazette deed Reappointments: Rias Baixas BV, Corujo BV and 2 others
Permanent representatives: Peter Vercaemst, Ward Vercaemst and Ciska Wyns9 points ▸
  • General meeting, 02-06-2022
  • Director reappointment, Rias Baixas BV (director)
  • Director reappointment, Corujo BV (director)
  • Director reappointment, Manipuro BV (director)
  • Director reappointment, Melissa Hellebuyck (director)
  • Permanent representative, Peter Vercaemst
  • Permanent representative, Ward Vercaemst
  • Permanent representative, Ciska Wyns
  • Board meeting, “Raad van Bestuur, vanaf heden” (deed in Dutch)

Open the act in the Belgian Official Gazette

2022
29-06
NBB filing Annual accounts 2021 filedPDF
full format · 32 days before the deadline
03-02
Gazette deed Permanent representatives: Sven Vansteelant and Jens Vanden Driessche
Appointment: AUDITAS BEDRIJFSREVISOREN BV (statutory auditor)4 points ▸
  • General meeting, 15-10-2021
  • Permanent representative, Sven Vansteelant
  • Permanent representative, Jens Vanden Driessche
  • Auditor appointment, AUDITAS BEDRIJFSREVISOREN BV (statutory auditor)

Open the act in the Belgian Official Gazette

2021
23-07
NBB filing Annual accounts 2020 filedPDF
abbreviated format · 8 days before the deadline
Show earlier events
2020
31-12
Financial Equity above €2mequity €2.6m ▲54.9%
With a profit in every financial year since 2018, equity grows to €2.6m.
17-07
NBB filing Annual accounts 2019 filedPDF
abbreviated format · 14 days before the deadline
2019
17-07
NBB filing Annual accounts 2018 filedPDF
abbreviated format · 14 days before the deadline
2018
17-07
NBB filing Annual accounts 2017 filedPDF
abbreviated format · 14 days before the deadline
2017
20-07
NBB filing Annual accounts 2016 filedPDF
abbreviated format · 11 days before the deadline
2006
18-09
Gazette deed IncorporationPDF
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.

Sources:Publications in the Belgian Official GazetteFilings with the National Bank

History

KEYPHARM was incorporated on 8 September 2006.1 Turnover grew from €11.1m in 2021 to €14.9m in 2025 and headcount from 14.1 full-time equivalents in 2018 to 18 in 2025.2

  1. 1KBO register
  2. 2National Bank, annual accounts 2018, 2021 and 2025

Next steps